课题基金 / 基金详情

MSKCC CENTER FOR IN VIVO MOLECULAR IMAGING IN CANCER

MSKCC CENTER FOR IN VIVO MOLECULAR IMAGING IN CANCER
MSKCC 癌症体内分子成像中心
批准号:
6608056
负责人:
Steven Mark Larson
金额:
$200.0万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-06-01 至 2005-05-31

项目摘要

项目成果

Steven Mark Larson的其他基金

相关文献

中文摘要
翻译
描述:(申请人描述) 随着对细胞和生物过程的更好理解的到来, 分子水平与新的生物试剂和 探测器,以及成像技术的最新发展和改进,它是 适当地将注意力集中在汇集这些进展上。更多 重要的是,人们认识到分子和基于细胞的成像可以影响 直接对癌症的治疗和诊断,以及发展和 新的分子疗法的测试将大大受益于 我们成像特定分子和细胞过程的能力方面的进展。在……里面 在过去的几年里,这个国家的几个团体(包括几个在 MSKCC)已经开始整合这些不同的学科,并取得了一些成功。 例如,MSKCC的多学科互动导致了 论证了体内转基因表达成像的可行性,以及 非侵入性“报告基因”成像的使用正在扩大到包括 在分子水平上的特定细胞过程。这个主题,翻译和 将基于分子和细胞的成像技术应用于临床 MSKCC计划和这项提议的优势,这一主题得到了贯彻 在本提案的整个结构和各个组成部分中 这项提案的愿景是通过与现有学科的相互作用 MSKCC,是:1)开发非侵入性成像范例,反映特定的 细胞/分子过程(如内源性基因表达)和 特定信号转导途径中的蛋白质相互作用;2) 对治疗基因的选择性扩增进行成像;3)监测 转基因T细胞的贩运和靶向;4)成像 体内肿瘤球体的生长和血管形成;5)核磁共振的应用 光谱和PET成像以优化化疗和基因治疗;6) 从分子和细胞角度对可卡霉素的抗肿瘤作用进行成像 7)代谢PET显像及分子病理学在临床中的应用 前列腺癌患者病情进展和C反应的评估 癌症;8)结合剂量学估计和分子靶蛋白成像 用86Y/90Y标记的抗CD19和抗CD2O抗体对患者进行检测。 这项提议的协调主题是分子和 以细胞为基础的成像对治疗和诊断有直接影响 癌症,并提供新的研究机会,将进一步我们的 对癌症、癌症进展和靶向治疗反应的了解 特定的分子过程。
英文摘要
DESCRIPTION: (Applicant's Description) With the advent of a better understanding of cell and biological processes at a molecular level coupled with the development of new biological reagents and probes, and recent developments and improvements in imaging technology, it is appropriate to focus attention on bringing together these advances. More importantly, it is recognized that molecular and cell-based imaging can impact directly on cancer treatment and diagnosis, and that the development and testing of new molecular-based therapies would benefit substantially from advances in our ability to image specific molecular and cell processes. In the last few years, several groups in this country (including several at MSKCC) have begun to integrate these diverse disciplines with some success. For example, multi-disciplinary interactions at MSKCC has led to the demonstration of the feasibility for imaging transgene expression in vivo, and the use of noninvasive "reporter gene" imaging is being expanded to include specific cell processes at a molecular level. This theme, the translation and implementation of molecular and cell-based imaging into the clinical arena, is a strength of the MSKCC program and this proposal, and this theme is carried throughout the structure and individual components of this proposal The vision of this proposal through the interaction of existing disciplines at MSKCC, is: 1) to develop noninvasive imaging paradigms that reflect specific cellular/molecular processes (such as endogenous gene expression) and protein-protein interactions within specific signal transduction pathways; 2) imaging the selective amplification of therapeutic genes; 3) monitoring the trafficking and targeting of genetically modified T cells; 4) imaging the growth and vascularization of tumor spheroids in vivo; 5) the use NMR spectroscopy and PET imaging to optimize chemotherapy and gene therapy; 6) imaging the anti-tumor effects of ancamycins ins at a molecular and cellular level; 7) the application of metabolic PET imaging and molecular-pathology in the assessment of disease progression anc response in patients with prostate cancer; 8) combining dosimetiry estimates and imaging of molecular targetins with 86Y/90Y- labeled anti-CD 19 and anti-CD2O antibodies in patients. The coordinating theme of this proposal is the potential for molecular and cell-based imaging to have a direct impact on the treatment and diagnosis of cancer, and to provide new research opportunities that will further our inderstanding of cancer, cancer progression and response to therapies targeted to specific molecular processes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Organization and Administration
  • 批准号:
    8725593
  • 项目类别:
  • 资助金额:
    $4.73万
  • 财政年份:
    2014
  • 负责人:
    Steven Mark Larson
  • 依托单位:
124I-cG250 ImmunoPET Imaging of Sunitinib Treatment Response in Renal Cell Cancer
  • 批准号:
    8338883
  • 项目类别:
  • 资助金额:
    $37.95万
  • 财政年份:
    2011
  • 负责人:
    Steven Mark Larson
  • 依托单位:
124I-cG250 ImmunoPET Imaging of Sunitinib Treatment Response in Renal Cell Cancer
  • 批准号:
    8257032
  • 项目类别:
  • 资助金额:
    $37.57万
  • 财政年份:
    2011
  • 负责人:
    Steven Mark Larson
  • 依托单位:
Molecular Imaging of Castrate- Resistance Metastatic Prostate Cancer
  • 批准号:
    7729472
  • 项目类别:
  • 资助金额:
    $11.17万
  • 财政年份:
    2008
  • 负责人:
    Steven Mark Larson
  • 依托单位: